SWOT Analysis

Strength: Presence of large pool of key players with strong financial capabilities for carrying out extensive R&D.
Weakness: High development cost of antibody drugs and long duration of clinical trials.
Opportunity: Rising healthcare expenditure in emerging economies and untapped growth potential in developing markets.
Threats: Patent expiries of blockbuster drugs and biosimilars entering the market.

Key Takeaways

The Global Antibodies Market Size is expected to witness high growth, exhibiting CAGR of 12.% over the forecast period, due to increasing prevalence of chronic diseases.

Regional analysis: North America dominated the global antibodies market in 2023 and is expected to maintain its leading position during the forecast period. This can be attributed to growing demand for monoclonal antibody therapeutics and strong presence of key market players in the region. Asia Pacific is expected to exhibit fastest growth over the forecast period supported by rising healthcare investments, increasing disposable income and growing awareness.

Key players: Novartis AG, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, AbbVie Inc., Sanofi, Eli Lilly and Co., Iovance Biotherapeutics, Inc., Ultragenyx Pharmaceutical Inc., and Kyowa Kirin Co., Ltd.

Read More - https://makuv.com/emerging-target-specific-antibodies-to-boost-growth-of-the-antibodies-market/